加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.4928
−US$0.0066 · -1.32%
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
收盘时
US$0.4928
−US$0.0066 · -1.32%
盘后
US$0.51
+US$0.0172 · +3.49%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
日内区间
当前US$0.4928
52周区间
当前US$0.4928
盘中时间采用ET。市场数据可能有所延迟。
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
日内区间
当前US$0.4928
52周区间
当前US$0.4928
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 21.43万 USD | 20.96万 USD | — | — | 16.49万 USD |
| 毛利 | −21.43万 USD | −20.96万 USD | — | — | −16.49万 USD |
| 研究与开发 | 915.65万 USD | 1190.66万 USD | 1481.97万 USD | 1765.55万 USD | 1224.05万 USD |
| 销售、一般及管理费用 | 1853.28万 USD | 1824.94万 USD | 2191.23万 USD | 1566.06万 USD | 1112.65万 USD |
| 营业费用 | 3831.14万 USD | 4199.57万 USD | 3673.2万 USD | 3331.6万 USD | 2336.7万 USD |
| 利息收入 | 11.01万 USD | 75.8万 USD | 117.94万 USD | 25.14万 USD | 26.18万 USD |
| 利息支出 | 26.78万 USD | — | — | — | 1.08万 USD |
| 折旧和摊销 | 21.43万 USD | 20.96万 USD | 19.43万 USD | 17.97万 USD | 16.49万 USD |
| 营业利润 | −3852.56万 USD | −4199.57万 USD | −3673.2万 USD | −3331.6万 USD | −2353.19万 USD |
| 净利润 | −3743.39万 USD | −3913.88万 USD | −3254.29万 USD | −3364.06万 USD | −2305.44万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
